BioSpace News Archive

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced the presentation of an analysis from its Phase 2a BALANCED study of efruxifermin (EFX) in patients with biopsy-confirmed F1-F3 fibrosis associated with non-alcoholic steatohepatitis (NASH).

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS).

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces the US Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to initiate the Orpheus Phase 2 study of Noema’s PDE10A inhibitor gemlapodect (NOE-105) in Childhood Onset Fluency Disorder (COFD, also known as stuttering).

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Tony Tripeny to its Board of Directors (the “Board”), effective June 23, 2022.

Enzyvant announced it is among the National Organization for Rare Disorders 2022 Industry Innovation Awards recipients for the development and U.S. Food and Drug Administration approval of RETHYMIC®, a one-time regenerative tissue-based therapy for pediatric congenital athymia.

Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, the Group has recently received the clinical trial approval for its R520A, a mRNA COVID-19 vaccine, from the Food and Drug Administration of the Philippines.

Wilmington, Delaware, United States: A sterilant is a sterilizing agent used by the medical industry to inactivate or destroy various types of microorganisms present in surgical instruments and medical supplies.

Prestige Biopharma Limited, a Singapore-based biopharmaceutical company with operations in USA and South Korea, announced that the U.S. Food and Drug Administration has approved the Phase 1/2a clinical trial of its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer.

Amberstone Biosciences is announcing the formation of a scientific advisory board comprised of industry leaders in drug delivery, oncology, immunology and pharmaceutical sciences.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced new positive clinical data in individuals vaccinated with a third dose of SCB-2019 as a homologous booster against the Omicron variant.